loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Viloxazine Hydrochloride

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Viloxazine Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 873Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Supernus Announces Qelbree™ sNDA for Adult Indication Accepted for Review by FDA
    Supernus Announces Qelbree™ sNDA for Adult Indication Accepted for Review by FDA

    02 Sep 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/09/02/2291229/19871/en/Supernus-Announces-Qelbree-sNDA-for-Adult-Indication-Accepted-for-Review-by-FDA.html

    GLOBENEWSWIRE
    02 Sep 2021
    Share Share
    Qelbree Now Available for Pediatric ADHD
    Qelbree Now Available for Pediatric ADHD

    24 May 2021

    // Brian Park, PharmD EMPR

    https://www.empr.com/home/news/qelbree-now-available-for-pediatric-adhd/#:~:text=Qelbree%E2%84%A2%20(viloxazine%20extended%2Drelease,inhibiting%20the%20reuptake%20of%20norepinephrine.

    Brian Park, PharmD EMPR
    24 May 2021
    Share Share